



## Sanofi Signs a Global Agreement with SUEZ environnement To Enhance Water and Waste Management

**Paris, France - July 2<sup>nd</sup> 2015 -** Sanofi and SUEZ environnement have signed an agreement aimed at optimizing the economic and environmental performance of Sanofi's manufacturing sites, in France and abroad, over a three-year period with the possibility of renewal.

Pursuant to the agreement, SUEZ environnement will develop tailor-made solutions aimed at:

- Improving the energy efficiency of Sanofi sites, by optimizing the operation of water and waste treatment systems and the sites' waste-to-energy performance; and,
- Conserving water resources, in particular by optimizing water management, treatment and recycling at production sites.

Already two major projects have been started in France under this agreement. The first is focused on modernizing and increasing the capacity of the wastewater treatment station at the biochemicals site in Saint-Aubin-lès-Elbeuf (Seine-Maritime), and the second is focused on building a waste-to-energy and volatile organic compound treatment unit for the chemicals site in Sisteron (Alpes-de-Haute-Provence).

"Managing the environmental impact of our industrial activities is a high-priority objective for Sanofi," said Olivier Brandicourt, Chief Executive Officer, Sanofi. "This agreement with SUEZ environnement will enable us to implement state-of-the-art technologies that will help make our water and waste management processes more eco-friendly."

"Conserving resources, such as water, has become a fundamental issue for industrial companies and a key factor in their competitiveness. We are delighted with this agreement with Sanofi, which is in line with our strategy of supporting industrial companies in sustainably managing their resources," said Jean-Louis Chaussade, Chief Executive Officer, SUEZ environnement.

## **About Sanofi**

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

## **About SUEZ environnement**

We are at the dawn of the resource revolution. Faced with a rising world population, increasing urbanization and the growing scarcity of natural resources, we must secure, optimize and recover resources for our future. SUEZ environnement (Paris: SEV, Brussels: SEVB) supplies 92 million people with drinking water, provides 65 million with sanitation services, and offers waste collection services for nearly 50 million people. Each year, it recovers 14 million metric tons of waste and produces 5,138 GWh of local renewable energy. With 80,990 employees, SUEZ environnement is



present on all of the inhabited continents and is a key player in the circular economy for sustainable resource management. In 2014, SUEZ environnement had sales of 14.3 billion euros.

## **Sanofi Forward-Looking Statements**

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forwardlooking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2014. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Contacts : Sanofi Media Relations Flore Larger

Tél.: + 33 (0) 1 53 77 46 46

mr@sanofi.com

Contacts: SUEZ environnement Media Relations Catherine Des Arcis

Tel: +33 (0) 1 58 81 54 23

catherine.desarcis@suez-env.com

**Investor Relations** Sébastien Martel

Tel.: +33 (0) 1 53 77 45 45

ir@sanofi.com

**Investor Relations** 

Tel: +33 (0) 1 58 81 24 95